Imiglucerase
This enzyme replacement therapy is used to treat Gaucher's disease, a genetic disorder in which a deficiency of the enzyme glucocerebrosidase causes a fatty substance to accumulate in organs including the liver, spleen, and bone marrow. Regular intravenous infusions of this recombinant enzyme help reduce organ enlargement, improve blood counts, and decrease bone complications. It has significantly improved the prognosis for patients with this condition.
Lĩnh vực điều trị
Cơ chế tác dụng
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
This enzyme replacement therapy is used to treat Gaucher's disease, a genetic disorder in which a deficiency of the enzyme glucocerebrosidase causes a fatty substance to accumulate in organs including the liver, spleen, and bone marrow. Regular intravenous infusions of this recombinant enzyme help reduce organ enlargement, improve blood counts, and decrease bone complications. It has significantly improved the prognosis for patients with this condition.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Imiglucerase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201632. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="imiglucerase"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/imiglucerase/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/imiglucerase/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/imiglucerase/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="imiglucerase"></drugfyi-drug>